Kyowa Kirin Co., Ltd. — Patent Portfolio
1 drug with active patents · 12 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Kyowa Kirin Co., Ltd.'s pharmaceutical portfolio is relatively weak with a high average vulnerability score, and the company faces a significant cliff year in 2026 with 1 drug losing exclusivity.
Portfolio overview Kyowa Kirin Co., Ltd. has a total of 43 drugs in its portfolio, with 1 of them having patents. The company holds 12 active US patents with an average vulnerability score of 52. Notably, there are no ironclad patents and no vulnerable patents in the portfolio. Additionally, the company has no biologics with BPCIA exclusivity.
Cliff calendar The company faces a significant cliff year in 2026, with 1 drug losing exclusivity. Specifically, Mitozytrex will lose exclusivity in 2026. This is the only notable cliff year in the near future.
Most exposed drugs The top drug facing near-term loss of exclusivity is Mitozytrex, with an earliest active patent expiry date of 2026-07-19, an average vulnerability score of 52, and no annual revenue data available. This drug has 12 patents and is the only notable drug in the portfolio.
Biologic exclusivity There are no biologics in the portfolio with BPCIA 12-year reference product exclusivity.
Strategic implications The company faces a total revenue at risk of $0 in the next 5 years. Considering the company's portfolio, it may be beneficial to explore lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue and competitiveness.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Mitozytrex (MITOMYCIN)
Cliff 2026 · 0y-
US12268745
Vuln 64
2031-01-20
This patent protects a hydrophilic biocompatible sustained-release material for injecting into internal body cavities to slowly release a therapeutic agent.
-
US9040074
Vuln 64
2031-01-20
This patent protects a hydrophilic biocompatible sustained-release material for injecting into internal body cavities to slowly release a therapeutic agent.
-
US9950069
Vuln 64
2031-01-20
This patent protects a hydrophilic biocompatible sustained-release material for injecting into internal body cavities to slowly release a therapeutic agent.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 7 patents
- Formulation 5 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Kyowa Kirin Co., Ltd.'s patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export